Navigation Links
Galileo Analytics Announces Agreement to Provide Analytic Component of ASCO's CancerLinQ Prototype
Date:12/13/2012

WASHINGTON, Dec. 13, 2012 /PRNewswire/ -- Galileo Analytics announced today that the American Society of Clinical Oncology® (ASCO), the world's leading professional organization representing physicians who care for people with cancer, has selected the Galileo Cosmos™ platform to serve as an analytic component of the CancerLinQ™ prototype, the first phase of the society's multi-phase effort to build a "rapid-learning system" in cancer care.

Galileo will provide real-time visual data mining and advanced analytics within the de-identified data of the breast cancer-specific prototype.  The ability to visually explore complex data and perform sophisticated analytics in real-time is at the essence of CancerLinQ.

ASCO's vision for CancerLinQ is a comprehensive, knowledge-generating computer network, which will pull in data from a variety of sources and make that data accessible and understandable to health care providers, researchers and patients.  Through CancerLinQ, ASCO seeks to speed the generation of new knowledge and understanding, so the cancer community can learn from all patients, not just the small percentage who participate in clinical trials.

The development of the prototype will allow ASCO to determine and overcome technological barriers to creating a more robust system encompassing all types of cancer, as well as identify requirements around the use of data standards.

"We are honored to be a part of the development of the CancerLinQ prototype," said Simon Fitall, CEO, Galileo Analytics.  "We designed Galileo Cosmos to enable the rapid exploration of the most complex health data available.  Our vision is to move data research out of the computer lab and into the hands of physicians, researchers and caregivers, giving them the power to find the meaningful connections that will improve care.  CancerLinQ embodies that vision, and we're thrilled to be part of making it a reality." 

For more information about CancerLinQ, visit www.asco.org/CancerLinQ.

About Galileo Analytics
Galileo Analytics is an advanced health data analytics and visual data mining company, which aims to democratize health data research. Galileo's visual data mining platform, Galileo Cosmos™, provides data researchers of all levels with an easy-to-use, cloud-based interface that enables real-time analysis of complex health data. For more information about Galileo Analytics and Galileo Cosmos™, visit www.galileoanalytics.com.

NOTE: ASCO® is a registered trademark of the American Society of Clinical Oncology®. Used with permission.  ASCO® is not a partner or affiliate of Galileo Analytics and does not recommend or endorse any vendor, product, or service.


'/>"/>
SOURCE Galileo Analytics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Accountable Care and Value-Based Purchasing Drives Adoption of Advanced Solutions for Health Data Analytics, Finds Frost & Sullivan
2. Campbell Alliance Launches Market Research and Analytics Group, Appoints Michael Turner as General Manager of Encuity Research
3. Medstreaming Launches Web-Based Analytics for All in One EMR/PACS/Practice Management Platform at HIMSS
4. Store-A-Tooth™ Dental Stem Cell Banking Announces Appointment of Dedicated Representative in South Florida
5. Accelr8 Announces NASDAQ Capital Market Listing
6. XBiotech Announces Positive Phase II Clinical Trial Results for Lead Candidate MABp1 in Acne Vulgaris
7. Milo Biotechnology Announces FDA Orphan Drug Designation for AAV1-FS344 for Treatment of Duchenne and Becker Muscular Dystrophy
8. Career Confidential Announces Release of New E-book About Using Recruiters
9. Pittcon Announces 2013 Award Recipients; New Award, Robert Boyle Prize for Analytical Science, Added to Technical Program
10. Innosight Announces Leadership Transition
11. My Cleaning Products Announces its Christmas Special, Sells Rusterizer at 20% Less
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... NextSteps ... and North America this May on the following dates: , ?    London, ... Taylor, Chairman of the Learning and Performance Institute will be the opening ...
(Date:4/26/2017)... , April 26, 2017  Genisphere LLC, ... platform, has signed a collaborative and sponsored research ... Silvia Muro . The overall goal of ... pharmacodynamics of various 3DNA designs and formulations after ... targeting diseases of the vasculature as well as ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... supplier of Common Lisp (CL) development tools, and market leader for Semantic ... key performance enhancements now available within the most effective system for developing and ...
(Date:4/25/2017)... , April 25, 2017 ... has licensed its novel immune-modulating technology to an undisclosed ... and allergy. Tregitopes, pronounced T·rej·itopes, are ... immunoglobulin by EpiVax CEO Annie De Groot ... intravenous immunoglobulin G, an autoimmune disease therapy, Tregitopes ...
Breaking Biology Technology:
(Date:4/6/2017)... , April 6, 2017 Forecasts ... ANPR, Document Readers, by End-Use (Transportation & Logistics, Government ... Oil, Gas & Fossil Generation Facility, Nuclear Power), Industrial, ... Other) Are you looking for a definitive ... ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
Breaking Biology News(10 mins):